Company Who this page is about. 1 identity field
Location
New York, NY
SEC filing record 1 source field
Fiscal year end
31 December
Actinium Pharmaceuticals, Inc. has filed 494 SEC EDGAR filings since 05 Feb 2007

SEC filing history

Showing 1-25 of 468 matching filings.

Per page
25
Current page
1
8-K File 001-36374

CURRENT REPORT

Filing date
29 May 2026
Reporting date
27 May 2026
Next action
Verify source filing
10-Q File 001-36374

QUARTERLY REPORT

Filing date
08 May 2026
Reporting date
31 Mar 2026
Next action
Verify source filing
10-K File 001-36374

ANNUAL REPORT

Filing date
30 Mar 2026
Reporting date
31 Dec 2025
Next action
Verify source filing
8-K/A File 001-36374

AMENDMENT NO.1 TO FORM 8-K

Filing date
26 Mar 2026
Reporting date
26 Nov 2025
Next action
Verify source filing
8-K File 001-36374

CURRENT REPORT

Filing date
13 Feb 2026
Reporting date
11 Feb 2026
Next action
Verify source filing
8-K File 001-36374

CURRENT REPORT

Filing date
26 Nov 2025
Reporting date
26 Nov 2025
Next action
Verify source filing
10-Q File 001-36374

QUARTERLY REPORT

Filing date
14 Nov 2025
Reporting date
30 Sep 2025
Next action
Verify source filing
ARS File 001-36374

ARS

Filing date
05 Nov 2025
Reporting date
31 Dec 2024
SEC evidence
Open document Open filing
Next action
Verify source filing
DEF 14A File 001-36374

PROXY STATEMENT

Filing date
05 Nov 2025
Reporting date
26 Nov 2025
Next action
Verify source filing
4

4 filing

Filing date
20 Aug 2025
Reporting date
18 Aug 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
10-Q File 001-36374

QUARTERLY REPORT

Filing date
08 Aug 2025
Reporting date
30 Jun 2025
Next action
Verify source filing
SCHEDULE 13G/A File 005-82467

SCHEDULE 13G/A filing

Filing date
29 Jul 2025
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SCHEDULE 13G/A File 005-82467

SCHEDULE 13G/A filing

Filing date
16 Jul 2025
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
10-Q File 001-36374

QUARTERLY REPORT

Filing date
09 May 2025
Reporting date
31 Mar 2025
Next action
Verify source filing
8-K File 001-36374

CURRENT REPORT

Filing date
09 May 2025
Reporting date
08 May 2025
Next action
Verify source filing
4

OWNERSHIP DOCUMENT

Filing date
02 Apr 2025
Reporting date
31 Mar 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
4

OWNERSHIP DOCUMENT

Filing date
02 Apr 2025
Reporting date
31 Mar 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
4

OWNERSHIP DOCUMENT

Filing date
02 Apr 2025
Reporting date
31 Mar 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
4

OWNERSHIP DOCUMENT

Filing date
02 Apr 2025
Reporting date
31 Mar 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
4

OWNERSHIP DOCUMENT

Filing date
02 Apr 2025
Reporting date
31 Mar 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
4

OWNERSHIP DOCUMENT

Filing date
02 Apr 2025
Reporting date
31 Mar 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
4

OWNERSHIP DOCUMENT

Filing date
02 Apr 2025
Reporting date
31 Mar 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
10-K File 001-36374

ANNUAL REPORT

Filing date
31 Mar 2025
Reporting date
31 Dec 2024
Next action
Verify source filing
8-K File 001-36374

CURRENT REPORT

Filing date
27 Nov 2024
Reporting date
27 Nov 2024
Next action
Verify source filing
10-Q File 001-36374

QUARTERLY REPORT

Filing date
14 Nov 2024
Reporting date
30 Sep 2024
Next action
Verify source filing
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .